Fixed dose combination of perindopril with indapamide in primary prevention of cerebrovascular complications among patients with metabolic syndrome and arterial hypertension

Aim. To study 24-week Fixed dose combination of perindopril with indapamide (Noliprel®) therapy effects on parameters of 24-hour blood pressure monitoring (BPM), carbohydrate, lipid, and purine metabolism, tissue insulin sensitivity, and cerebral perfusion in patients with mild to moderate arterial hypertension (AH) and metabolic syndrome (MS). Material and methods. Twenty-six patients with mild to moderate AH and MS participated in the study. All patients were administered Noliprel® or Noliprel® Forte (one tablet per day, in the morning). At baseline and 24 weeks later, all patients underwent 24-hour BPM, manual BP measurement, carbohydrate and lipid metabolism, peripheral tissue insulin sensitivity assessment, as well as cerebral scintigraphy, for cerebral perfusion assessment. Results. Noliprel® therapy was associated with target BP level achievement in 84% of the patients, and significant decrease in virtually all mean circadian BP profile parameters. Lipid metabolism parameters substantially improved, glycemia level decreased, initially reduced insulin sensitivity index increased. In all participants, bilateral cerebral perfusion, severely impaired at baseline, substantially improved. Conclusion. Noliprel® therapy in patients with AH and MS was associated with BP reduction, together with endothelial function improvement, peripheral tissue insulin sensitivity increase, and positive metabolic effects, that resulted in substantial improvement of cerebral perfusion.

1. Рекомендации по профилактике, диагностике и лечению артериальной гипертензии. Москва 2004.

2. Мычка В.Б., Масенко В.Б., Творогова М.Г. и др. Применение периндоприла у больных мягкой и умеренной артериальной гипертензией и метаболическим синдромом. Артер гиперт 2002; 8(1): 178-81.

3. Чазова, И.Е., Мычка В.Б., Горностаев В.В. и др. Цереброваскулярные осложнения у больных артериальной гипертензией: первичная и вторичная профилактика. Cons med 2003; 5(2): 61-4.

4. PROGRESS Management Committee. PROGRESS: Perindopril Protection Against Recurrent Stroke Study: status in March 1997. J Hum Hypertens 1998; 12: 627-9.

5. Giverts MM. Manipulation of the renin-angiotensin system. Circulation 2001; 104(5): 14-8.

6. Griendling KK, Minieri CA, Ollerenshow JD, et al. Angiotensin II stimulates NADH and NADH oxydase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74(6): 1141-8.

7. Bossaller C, Auch-Schwelk W, Grafe M. Effects of converting enzyme inhibition on endothelial bradykinin metabolism and endothelialdependent vascular relaxion. Agets Actions 1992; 38: 171-7.